{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:08:22Z","timestamp":1767848902363,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T00:00:00Z","timestamp":1658880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.037","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T08:24:42Z","timestamp":1659515082000},"page":"5347-5355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety"],"prefix":"10.1016","volume":"40","author":[{"given":"Beatriz P.","family":"Quiambao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan G.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Bosch Castells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christele","family":"Augard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Delore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Houillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.07.037_b0005","unstructured":"World Health Organization. WHO fact sheet: Rabies. 17 May 2021. Available at https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/rabies. Accessed 23 Septl 2021; 2021."},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.037_b0010","doi-asserted-by":"crossref","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the Global Burden of Endemic Canine Rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PLoS NeglTrop Dis"},{"key":"10.1016\/j.vaccine.2022.07.037_b0015","doi-asserted-by":"crossref","unstructured":"Tenzin, Ward MP. Review of rabies epidemiology and control in South, South East and East Asia: past, present and prospects for elimination. Zoonoses Public Health 2012;59:451\u201367.","DOI":"10.1111\/j.1863-2378.2012.01489.x"},{"key":"10.1016\/j.vaccine.2022.07.037_b0020","first-page":"309","article-title":"Rabies vaccines: WHO position paper","volume":"85","author":"World Health Organization","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"issue":"37","key":"10.1016\/j.vaccine.2022.07.037_b0025","first-page":"5500","article-title":"Rabies vaccines: WHO position paper, April 2018 - Recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2022.07.037_b0030","article-title":"Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies - Recommendations of the Advisory Committee on Immunization Practices","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.037_b0035","doi-asserted-by":"crossref","first-page":"e0004846","DOI":"10.1371\/journal.pntd.0004846","article-title":"Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 1990\u20132015","volume":"10","author":"Moro","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.037_b0040","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1080\/21645515.2015.1048938","article-title":"Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases","volume":"11","author":"Narayana","year":"2015","journal-title":"Human Vaccines Immunotherap"},{"key":"10.1016\/j.vaccine.2022.07.037_b0045","doi-asserted-by":"crossref","unstructured":"Rupprecht C, Nagarajan T, Ertl H. Rabies Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin's Vaccines (Seventh Edition): Elsevier. 2017:918-42.e12.","DOI":"10.1016\/B978-0-323-35761-6.00049-3"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.037_b0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4161\/hv.4.4.5588","article-title":"An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects","volume":"4","author":"Sudarshan","year":"2008","journal-title":"Human Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.037_b0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tmaid.2007.07.004","article-title":"Preventing rabies with the Verorab vaccine: 1985\u20132005 Twenty years of clinical experience","volume":"5","author":"Toovey","year":"2007","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.037_b0060","unstructured":"World Health Organization. WHO expert consultation on rabies: third report: WHO Technical Report Series No. 1012. 2018. Available at: http:\/\/appswhoint\/iris\/bitstream\/handle\/10665\/272364\/9789241210218-engpdf?ua=1 Accessed 10 November 2021; 2018."},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.037_b0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.vaccine.2011.11.007","article-title":"Rabies vaccination for international travelers","volume":"30","author":"Gautret","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.037_b0070","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jtm\/tay062","article-title":"Perceptions of rabies risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK","volume":"26","author":"Marano","year":"2019","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2022.07.037_b0075","doi-asserted-by":"crossref","unstructured":"Yates JA, Rao SR, Walker AT, Esposito DH, Sotir M, LaRocque RC, et al. Characteristics and preparation of the last-minute traveler: analysis of vaccine usage in the Global TravEpiNet Consortium. J Travel Med. 2019;26.","DOI":"10.1093\/jtm\/taz031"},{"issue":"18","key":"10.1016\/j.vaccine.2022.07.037_b0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.15585\/mmwr.mm7118a2","article-title":"Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.07.037_b0085","unstructured":"Sanofi. Verorab package insert, Thailand. Available at https:\/\/www.fda.moph.go.th\/sites\/drug\/Shared%20Documents\/Vaccine\/U1DR1C1042470033911C-SPC.pdf. Accessed 22 June 2022; 2016."},{"key":"10.1016\/j.vaccine.2022.07.037_b0090","unstructured":"Department of Health RotP. Revised Guidelines on the Management of Rabies Exposures. Available at https:\/\/www.psmid.org\/wp-content\/uploads\/2020\/03\/CPG-rabies-AO-2018-0013.pdf. Accessed 11 July 2022; 2018."},{"key":"10.1016\/j.vaccine.2022.07.037_b0095","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.vaccine.2018.08.034","article-title":"Introduction of intradermal rabies vaccination \u2013 A paradigm shift in improving post-exposure prophylaxis in Asia","volume":"37","author":"Gongal","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.037_b0100","unstructured":"Sanofi. Imovax Rabies Package Insert. Available at https:\/\/www.fda.gov\/media\/75709\/download. Accessed 22 June 2022; 2019."},{"key":"10.1016\/j.vaccine.2022.07.037_b0105","first-page":"279","article-title":"Laboratory techniques in rabies: the NIH test for potency. Monograph series World Health","author":"Seligmann","year":"1973","journal-title":"Organization"},{"key":"10.1016\/j.vaccine.2022.07.037_b0110","doi-asserted-by":"crossref","first-page":"112626","DOI":"10.1016\/j.jim.2019.06.017","article-title":"Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus","volume":"474","author":"Timiryasova","year":"2019","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2022.07.037_b0115","doi-asserted-by":"crossref","unstructured":"Soentjens P, Andries P, Aerssens A, Tsoumanis A, Ravinetto R, Heuninckx W, et al. Preexposure Intradermal Rabies Vaccination: A Noninferiority Trial in Healthy Adults on Shortening the Vaccination Schedule From 28 to 7 Days. Clin Infect Dis: Off Publ Infect Dis Soc Am 2019;68:607-14.","DOI":"10.1093\/cid\/ciy513"},{"key":"10.1016\/j.vaccine.2022.07.037_b0120","doi-asserted-by":"crossref","unstructured":"Mills DJ, Lau CL, Fearnley EJ, Weinstein P. The immunogenicity of a modified intradermal pre-exposure rabies vaccination schedule \u2013 a case series of 420 travelers. J Travel Med 2011;18:327-32.","DOI":"10.1111\/j.1708-8305.2011.00540.x"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.037_b0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0264-410X(89)90050-9","article-title":"Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells","volume":"7","author":"Ajjan","year":"1989","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.037_b0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2310\/7060.2004.19001","article-title":"Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine","volume":"11","author":"Arora","year":"2004","journal-title":"J Travel Med"},{"issue":"8","key":"10.1016\/j.vaccine.2022.07.037_b0135","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/jcm.28.8.1847-1850.1990","article-title":"Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods","volume":"28","author":"Kitala","year":"1990","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.07.037_b0140","doi-asserted-by":"crossref","unstructured":"Sabchareon A, Lang J, Attanath P, Sirivichayakul C, Pengsaa K, Le Mener V, et al. A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. Clin Infect Dis: Off Publ Infect Dis Soc Am 1999;29:141-9.","DOI":"10.1086\/520143"},{"key":"10.1016\/j.vaccine.2022.07.037_b0145","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab059","article-title":"Efficacy of one-dose intramuscular rabies vaccine as pre-exposure prophylaxis in travellers","volume":"28","author":"Mills","year":"2021","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2022.07.037_b0150","doi-asserted-by":"crossref","unstructured":"Soentjens P, De Koninck K, Tsoumanis A, Herssens N, Van Den Bossche D, Terryn S, et al. Comparative Immunogenicity and Safety Trial of 2 Different Schedules of Single-visit Intradermal Rabies Postexposure Vaccination. Clin Infect Dis: Off Publ Infect Dis Soc Am 2019;69:797-804.","DOI":"10.1093\/cid\/ciy983"},{"issue":"19","key":"10.1016\/j.vaccine.2022.07.037_b0155","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.vaccine.2011.12.028","article-title":"One clinic visit for pre-exposure rabies vaccination (a preliminary one year study)","volume":"30","author":"Khawplod","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.037_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax033","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","volume":"24","author":"Jonker","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2022.07.037_b0165","doi-asserted-by":"crossref","unstructured":"Endy TP, Keiser PB, Wang D, Jarman RG, Cibula D, Fang H, et al. Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis. J Infect Dis 2020;221:1494-8.","DOI":"10.1093\/infdis\/jiz645"},{"key":"10.1016\/j.vaccine.2022.07.037_b0170","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/cid\/ciy420","article-title":"Rabies Antibody Response After Booster Immunization: A Systematic Review and Meta-analysis","volume":"67","author":"Langedijk","year":"2018","journal-title":"Clin Infect Dis: Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.07.037_b0175","doi-asserted-by":"crossref","unstructured":"Wieten RW, Leenstra T, van Thiel PP, van Vugt M, Stijnis C, Goorhuis A, et al. Rabies vaccinations: are abbreviated intradermal schedules the future? Clin Infect Dis: Off Publ Infect Dis Soc Am 2013;56:414-9.","DOI":"10.1093\/cid\/cis853"},{"key":"10.1016\/j.vaccine.2022.07.037_b0180","article-title":"Long-term Memory Response After a Single Intramuscular Rabies Booster Vaccination 10\u201324 Years After Primary Immunization","author":"De Pijper","year":"2021","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2022.07.037_b0185","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2018.11.072","article-title":"An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route","volume":"37","author":"Denis","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.037_b0190","doi-asserted-by":"crossref","DOI":"10.1590\/S0034-89102010005000005","article-title":"Equival\u00eancia e avalia\u00e7\u00e3o da necessidade de sorologia de controle entre esquemas de pr\u00e9-exposi\u00e7\u00e3o \u00e0 raiva humana","volume":"44","author":"Cunha","year":"2010","journal-title":"Rev Sa\u00fade P\u00fablica"},{"key":"10.1016\/j.vaccine.2022.07.037_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-004074","article-title":"Vaccinating children in high-endemic rabies regions: what are we waiting for?","volume":"6","author":"Soentjens","year":"2021","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2022.07.037_b0200","article-title":"Purified Vero Cell Rabies Vaccine (PVRV, Verorab((R))): A Systematic Review of Intradermal Use Between 1985 and 2019","volume":"5","author":"Moulenat","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2022.07.037_b0205","series-title":"Rabies Scientific Basis of the Disease and Its Management","first-page":"445","article-title":"Measures of Rabies Immunity","author":"Moore","year":"2020"},{"key":"10.1016\/j.vaccine.2022.07.037_b0210","doi-asserted-by":"crossref","first-page":"9893","DOI":"10.1038\/s41598-020-66754-8","article-title":"Preparation and qualification of internal rabies reference standards for use in the rabies rapid fluorescent focus inhibition test","volume":"10","author":"Timiryasova","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.07.037_b0215","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.vaccine.2013.02.058","article-title":"A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial","volume":"31","author":"Pichon","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22009239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:16:40Z","timestamp":1759403800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22009239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":43,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22009239"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess immunogenicity and safety","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}